Highland Capital Management (Tennessee)’s Neurocrine Biosciences NBIX Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,901	Closed	-$854K	–	344
2021 Q3	$854K	Sell	8,901 -792	-8%	-$74.8K	0.05%	252
2021 Q2	$943K	Sell	9,693 -136	-1%	-$13K	0.06%	242
2021 Q1	$956K	Sell	9,829 -773	-7%	-$81.1K	0.06%	243
2020 Q4	$1.02M	Sell	10,602 -565	-5%	-$54.6K	0.07%	233
2020 Q3	$1.07M	Buy	11,167 +354	+3%	+$40.9K	0.08%	213
2020 Q2	$1.32M	Sell	10,813 -990	-8%	-$109K	0.1%	194
2020 Q1	$1.02M	Buy	+11,803	New	+$1.16M	0.1%	193
2019 Q4	–	Sell	-9,858	Closed	-$888K	–	322
2019 Q3	$888K	Buy	+9,858	New	+$921K	0.07%	224
2019 Q1	–	Sell	-8,762	Closed	-$626K	–	340
2018 Q4	$626K	Buy	+8,762	New	+$839K	0.05%	257
2018 Q3	–	Sell	-6,554	Closed	-$644K	–	347
2018 Q2	$644K	Buy	+6,554	New	+$587K	0.05%	263

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Highland Capital Management (Tennessee)'s NBIX Position: Q4 2021 in Review

Highland Capital Management (Tennessee) sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 8,901 shares — an estimated $854K sold.

Highland Capital Management (Tennessee) first reported a position in NBIX in Q2 2018 and held it in 10 quarters. The position peaked at $1.32M in Q2 2020. 406 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

Highland Capital Management (Tennessee) reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
Highland Capital Management (Tennessee) sold 8,901 Neurocrine Biosciences shares in Q4 2021, an estimated $854K.
Highland Capital Management (Tennessee) first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 10 quarters.
Highland Capital Management (Tennessee)'s Neurocrine Biosciences position peaked at $1.32M in Q2 2020.
406 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q4 2021, filed 28 Jan 2022.